Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors ? a CESAR study (Central European Society for Anticancer Drug Research ? EW
| Autor: | Ulrich Jaehde, Christian Dittrich, Margit Gneist, Michael A. Jakupec, Bernhard K. Keppler, Andreas Hochhaus, A. Drescher, R.D. Hofheinz, N Graf von Keyserlingk |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
Societies Scientific Pharmacology Dose-Response Relationship Drug Maximum Tolerated Dose business.industry Administration Oral Antineoplastic Agents Oxyquinoline Anticancer drug Phase i study Tris(8-quinolinolato)gallium (III) Early results Neoplasms Maximum tolerated dose Organometallic Compounds Humans Medicine Female Pharmacology (medical) In patient business |
| Zdroj: | Europe PubMed Central |
| ISSN: | 0946-1965 |
| DOI: | 10.5414/cpp43590 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|